Bright, S A <br/><br/>
Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers.  [electronic resource] 

 -  Oncology reports  May 2019 
 - 3127-3136 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-2431 
<br/><br/><label>Standard No.: </label>10.3892/or.2019.7068  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--chemistry<br/>Apoptosis--drug effects<br/>Biomarkers, Tumor--genetics<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Drug Screening Assays, Antitumor<br/>Drug Synergism<br/>Female<br/>Humans<br/>Inhibitory Concentration 50<br/>Leukemia, Lymphocytic, Chronic, B-Cell--blood<br/>Leukocytes, Mononuclear<br/>Male<br/>Middle Aged<br/>Nitro Compounds--chemistry<br/>Primary Cell Culture<br/>Prognosis<br/>Purines--pharmacology<br/>Quinazolinones--pharmacology<br/>Structure-Activity Relationship<br/>Styrenes--chemistry